Abstract
Type 2 diabetes is a chronic disease characterized by impaired insulin action, progressive β-cell dysfunction as well as abnormalities in pancreatic α-cell function and postprandial substrate delivery. These pathophysiologic defects result in both persistent and progressive hyperglycemia, resulting in increased risk of both microvascular and cardiovascular complications. Traditional treatments for type 2 diabetes have focused on impaired insulin secretion and insulin resistance. These strategies are typically used in a stepwise manner: employing oral glucose lowering agents, followed by insulin therapy. This traditional approach fails to address the progressive decline in β-cell function. Moreover, these therapies are often associated with weight gain in overweight or obese patients with type 2 diabetes. Both exogenous insulin and insulin secretagogues are associated with an increased risk of hypoglycemia. Recently, new treatments that leverage the glucoregulatory effects of incretin hormones, such as glucagon-like peptide-1 have been introduced. Both incretin mimetics and DPP-4 inhibitors address both the underlying pathophysiology and overcome several of the limitations of established therapies by providing improvements in glycemia, and control of body weight with minimal risk of hypoglycemia.
Keywords: Body weight, DPP-4 inhibitor, Glycemia, Incretin mimetic, Type 2 diabetes
Current Diabetes Reviews
Title: Emerging Incretin-Based Therapies for Type 2 Diabetes: Incretin Mimetics and DPP-4 Inhibitors
Volume: 4 Issue: 2
Author(s): Anthony Stonehouse, Ted Okerson, David Kendall and David Maggs
Affiliation:
Keywords: Body weight, DPP-4 inhibitor, Glycemia, Incretin mimetic, Type 2 diabetes
Abstract: Type 2 diabetes is a chronic disease characterized by impaired insulin action, progressive β-cell dysfunction as well as abnormalities in pancreatic α-cell function and postprandial substrate delivery. These pathophysiologic defects result in both persistent and progressive hyperglycemia, resulting in increased risk of both microvascular and cardiovascular complications. Traditional treatments for type 2 diabetes have focused on impaired insulin secretion and insulin resistance. These strategies are typically used in a stepwise manner: employing oral glucose lowering agents, followed by insulin therapy. This traditional approach fails to address the progressive decline in β-cell function. Moreover, these therapies are often associated with weight gain in overweight or obese patients with type 2 diabetes. Both exogenous insulin and insulin secretagogues are associated with an increased risk of hypoglycemia. Recently, new treatments that leverage the glucoregulatory effects of incretin hormones, such as glucagon-like peptide-1 have been introduced. Both incretin mimetics and DPP-4 inhibitors address both the underlying pathophysiology and overcome several of the limitations of established therapies by providing improvements in glycemia, and control of body weight with minimal risk of hypoglycemia.
Export Options
About this article
Cite this article as:
Stonehouse Anthony, Okerson Ted, Kendall David and Maggs David, Emerging Incretin-Based Therapies for Type 2 Diabetes: Incretin Mimetics and DPP-4 Inhibitors, Current Diabetes Reviews 2008; 4 (2) . https://dx.doi.org/10.2174/157339908784220705
DOI https://dx.doi.org/10.2174/157339908784220705 |
Print ISSN 1573-3998 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6417 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
General Principles for the Treatment of Non-Infectious Uveitis
Inflammation & Allergy - Drug Targets (Discontinued) Prospectives of Solid Self-microemulsifying Systems in Novel Drug Delivery
Current Drug Delivery Incretin Analogues that have been Developed to Treat Type 2 Diabetes Hold Promise as a Novel Treatment Strategy for Alzheimers Disease
Recent Patents on CNS Drug Discovery (Discontinued) Preface
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) The Impact of Natural Compounds on the Treatment of Neurodegenerative Diseases
Current Organic Chemistry Bio-inspired Biomaterials and their Drug Delivery Perspectives - A Review
Current Drug Metabolism Safety of SGLT2 Inhibitors in Patients with Diabetes Mellitus
Current Drug Safety In Silico Computations of Selective Phytochemicals as Potential Inhibitors Against Major Biological Targets of Diabetes Mellitus
Current Computer-Aided Drug Design Thiazolidine: A Potent Candidate for Central Nervous System Diseases
Central Nervous System Agents in Medicinal Chemistry NMNAT Expression and its Relation to NAD Metabolism
Current Medicinal Chemistry Fluorescent Substrates Useful as High Throughput Screening Tools for ADAM9
Combinatorial Chemistry & High Throughput Screening Preface:
Clinical Immunology, Endocrine & Metabolic Drugs (Discontinued) Metformin and Energy Metabolism in Breast Cancer: From Insulin Physiology to Tumour-initiating Stem Cells
Current Molecular Medicine In Silico Analysis of Compounds Derived from Perovskia Atriplicifolia for their Antidiabetic Potential
Letters in Drug Design & Discovery Current Landscape of Natural Products against Coronaviruses: Perspectives in COVID-19 Treatment and Anti-viral Mechanism
Current Pharmaceutical Design PPARγ: Potential Therapeutic Target for Ailments Beyond Diabetes and its Natural Agonism
Current Drug Targets Gliclazide, Inflammation and Atherosclerosis
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry How Close are We in Achieving Safe, Affordable and Reversible Male Contraceptives?
Endocrine, Metabolic & Immune Disorders - Drug Targets Pathogenesis of Type 1 Diabetes: Regulation of Adhesion Molecules and Immune Cell Trafficking
Current Immunology Reviews (Discontinued) Vasculitis Beyond the Kidneys
Clinical Immunology, Endocrine & Metabolic Drugs (Discontinued)